Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Institute of Medical Genetics and Applied Genomics, |
RCV001268364 | SCV001447238 | pathogenic | not provided | 2020-10-23 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002568716 | SCV003444600 | pathogenic | Primary ciliary dyskinesia | 2023-06-13 | criteria provided, single submitter | clinical testing | This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Glu834Glyfs*255) in the RPGR (ORF15) gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 319 amino acid(s) of the RPGR (ORF15) protein. This premature translational stop signal has been observed in individuals with X-linked retinitis pigmentosa (PMID: 12657579, 18552978, 30193314). This variant is also known as g.ORF15+748delA. ClinVar contains an entry for this variant (Variation ID: 975147). This variant disrupts a region of the RPGR (ORF15) protein in which other variant(s) (p.Leu1130Lysfs*13) have been determined to be pathogenic (PMID: 22264887; Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
Institute of Human Genetics, |
RCV004814028 | SCV005072239 | pathogenic | Retinal dystrophy | 2019-01-01 | criteria provided, single submitter | clinical testing | |
Blueprint Genetics | RCV001251609 | SCV001427309 | pathogenic | Retinitis pigmentosa 3 | no assertion criteria provided | clinical testing |